T-ALL

IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in American Society of Gene & Cell Therapy’s Journal, Molecular Therapy

Retrieved on: 
수요일, 8월 18, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dai, RRMM, CAR, Publishing, Program, Efficiency, Research, Huazhong University of Science and Technology, MCL, Epitope, Mutation, Risk, Chronic lymphocytic leukemia, Genetics, Hematopoietic stem cell transplantation, CD5, Medicine, VH, CRISPR, CMC, T-ALL, CLL, Paper, Cell, Huachung University, TCL, Technology, Cell therapy, Hope, Antibody, NMPA, Biotechnology, Degenerative disease, Fragment crystallizable region, Neoplasm, Tongji Hospital station, Molecular Therapy, Gene, Thymocyte, Transplant, Cancer, Society, Antigen, Mantle cell lymphoma, Chemistry, Gene editing, Multimedia, Western literature, Leukemia, HSCT, Patient, Vaccine

View the full release here: https://www.businesswire.com/news/home/20210818005265/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210818005265/en/
    Screenshot of IASO Bios published preclinical results (source: cell.com) (Graphic: Business Wire)
    Molecular Therapy is the official periodical of the American Society of Gene & Cell Therapy, and is published under Cell.
  • In recent years, CAR-T technology has seen numerous breakthroughs and achieved tremendous progress with the development of targets for the treatment B cell malignancies.
  • T cell malignancies include T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoma (TCL)1.
  • CD5 is also expressed in certain B cell malignancies, making CD5 a valid target for the treatment of both T cell and B cell malignancies.

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
금요일, 8월 13, 2021
European Society for Medical Oncology, Plantar fibromatosis, MM, BCMA, Oncology, Doctor of Philosophy, Pivotal, AYLA, Clinical trial, GSI, Congress, Research, Adenoid cystic carcinoma, Company, Aggressive fibromatosis, Multiple myeloma, Cancer, Patient, GLOBE, Novartis, Treatment, TNBC, D, FDA, ESMO, T-ALL, Neoplasm, T-Cell Acute Lymphoblastic Leukemia, Nasdaq, Therapy, ACC, Pharmaceutical industry

REHOVOT, Israel and WILMINGTON, Del., Aug. 13, 2021 (GLOBE NEWSWIRE) --  Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the period ended June 30, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs.

Key Points: 
  • Ayala is well positioned for strong clinical progress throughout the remainder of this year.
  • Collaboration Revenue: Collaboration revenue was $0.8 million for the second quarter of 2021, as compared to $1.0 million for the same period in 2020.
  • R&D Expenses: Research and development expenses were $8.1 million for the second quarter of 2021, compared to $5.1 million for the same period in 2020.
  • G&A Expenses: General and administrative expenses were $2.5million for the second quarter of 2021, compared to $1.5 million for the same period in 2020.